STOCK TITAN

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs for virology and immunology, has announced its participation at the Jefferies Global Healthcare Conference. The event will feature a fireside chat with President and CEO Jay R. Luly, Ph.D., and Chief Product Strategy Officer Tara L. Kieffer, Ph.D. The session is set for June 5, 2024, at 7:30 a.m. ET in New York, NY. A live webcast of the discussion will be available on Enanta's website, with a replay accessible for at least 30 days post-event.

Positive
  • Participation in a high-profile conference like Jefferies Global Healthcare Conference can enhance Enanta's visibility in the biotechnology industry.
  • The involvement of top executives in the event may boost investor confidence and demonstrate leadership commitment.
  • Availability of a live webcast and subsequent replay increases accessibility for investors and stakeholders, potentially widening the audience.
Negative
  • The press release lacks specific financial or clinical data updates, which investors typically look for in such announcements.
  • No new product developments or business milestones are mentioned, limiting immediate impact on stock performance.
  • Absence of detailed strategic insights or future plans could be seen as a missed opportunity to attract investor interest.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.

Media and Investors:

Jennifer Viera

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What is the date of Enanta Pharmaceuticals' participation at the Jefferies Global Healthcare Conference?

Enanta Pharmaceuticals will participate on June 5, 2024.

Who are the Enanta executives speaking at the Jefferies Global Healthcare Conference?

Jay R. Luly, Ph.D., President and CEO, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer.

Where can I access the live webcast of Enanta's presentation?

The live webcast will be available on the 'Events and Presentations' section of the 'Investors' page on Enanta's website.

Will there be a replay available for Enanta's presentation at the Jefferies Global Healthcare Conference?

Yes, a replay will be available following the presentation and will be archived for at least 30 days.

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

ENTA Rankings

ENTA Latest News

ENTA Stock Data

342.05M
21.18M
6.09%
107.12%
13.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WATERTOWN